Artiva grants director Hougen 16,250 stock options
Artiva Biotherapeutics disclosed a new stock option grant to a director that vests in 2027, adding 16,250 options at a $10.42 exercise price.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elizabeth L. Hougen received a grant of 16,250 director stock options on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036. The award vests in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting, and no Rule 10b5-1 trading plan is reported.
Insider Trade Summary
Grant/Award: 16,250 shares
Grant/Award
1 txn
Insider
HOUGEN ELIZABETH L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) F1 | 16,250 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 16,250 contracts (Direct)
Holdings Before and After:
Director Stock Option (Right to Buy), 0 to 16,250 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.
Key Figures
Options granted: 16,250 options
Exercise price: $10.42 per share
Underlying shares: 16,250 shares
+3 more
6 metrics
Options granted
16,250 options
Director stock option grant on September 10, 2026
Exercise price
$10.42 per share
Exercise price of director stock option grant
Underlying shares
16,250 shares
Common shares underlying the director stock options
Expiration date
September 9, 2036
Option expiration for the director stock option grant
Vesting date
Earlier of September 10, 2027, or 2027 annual meeting
Full vesting trigger for the 16,250 options
Post-transaction option holdings
16,250 options
Director’s direct holdings after reported grant
Key Terms
Director Stock Option (Right to Buy), exercise price, vest in full, annual stockholder meeting
4 terms
Director Stock Option (Right to Buy) financial
"security titled "Director Stock Option (Right to Buy)" was granted"
exercise price financial
"has an exercise price of $10.42 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"shares subject to the option will vest in full on the earlier"
annual stockholder meeting regulatory
"earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ARTV disclose about Elizabeth L. Hougen’s Form 4 transaction?
ARTV disclosed that director Elizabeth L. Hougen received a grant of 16,250 stock options on September 10, 2026. These options are a compensation-related award, not an open-market purchase or sale of common shares.
What are the key terms of the 16,250 director stock options reported by ARTV?
The award covers 16,250 options to buy Artiva common stock at an exercise price of $10.42 per share. The options are held directly by the director and expire on September 9, 2036 if not exercised earlier.
When do the stock options granted to the ARTV director vest?
The 16,250 options will vest in full on the earlier of September 10, 2027, or the date of Artiva’s 2027 annual stockholder meeting, according to the footnote describing the vesting schedule.
How many ARTV options does the director hold after this Form 4 transaction?
After the reported grant, the director holds 16,250 stock options directly, as stated by the post-transaction holdings figure on the Form 4 for this option award.
Was the ARTV director’s option grant made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that this grant was made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.
What type of security is involved in the ARTV Form 4 filing for the director?
The filing reports a Director Stock Option (Right to Buy), a derivative security that is exercisable into 16,250 shares of Artiva common stock at the stated exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
